New Index Shows AI Chatbots Send Aesthetic Patients to a Handful of Big Brands, Here's Why That Matters
A 2026 industry report finds that ChatGPT, Claude, Gemini and other AI tools overwhelmingly point people toward a small set of household-name toxins and fillers when asked about treatments. Here is what the data shows, and why it is still worth talking to a real local provider.
Key takeaways
- A new 2026 industry index found that just 25 brands capture roughly 95% of all AI citation share when people ask chatbots about aesthetic treatments.
- Two pharmaceutical companies alone, whose portfolios include Botox, Juvederm and Dysport, account for about 80% of drug and device mentions combined.
- Researchers tested 65 patient-style questions across five AI systems and scored 92 candidate brands on how often and how prominently each appeared.
- The findings are about brand visibility in AI answers, not a ranking of safety or results, so they should not replace a real consultation with a licensed local provider.
Figures drawn from the Med Spa and Aesthetic Medicine AI Visibility Index 2026 and accompanying press coverage; brand visibility is not a measure of safety or fit for any individual.
What the New Report Actually Measured
A market research firm released a Med Spa and Aesthetic Medicine AI Visibility Index in June 2026, built to answer a simple question: when someone types a treatment question into ChatGPT, Claude, Perplexity, Gemini or Google's AI Overviews, whose name comes back first. Analysts ran 65 patient-intent prompts, covering everything from wrinkle relaxers to body contouring to how to pick a provider, and tracked which of 92 candidate brands showed up and how prominently.
The headline number is stark. Just 25 brands were found to control about 95% of all AI citation share across the category, which the report pegs at roughly a 25 billion dollar market growing at a double-digit pace. The remaining slice, an estimated 5%, is split among the thousands of independent med spas and smaller device makers competing for attention.
A Two-Company Duopoly at the Top
Zoom in further and the concentration gets sharper. Two pharmaceutical parent companies were found to account for about 80% of all drug and device citations combined. One holds roughly 47% of that share through its toxin, filler and body-contouring lines, while the other holds about 33% through its own toxin and filler portfolio. Individual brand scores followed the same pattern, with the leading neurotoxin brand pulling the single highest score among everything tested, essentially becoming shorthand for the whole treatment category in many AI-generated answers.
None of this is a judgment about which product works best for a given face or budget. It is a measure of how often a name gets repeated back when an AI system is asked a broad question, which tends to reward brands with the largest advertising footprint, the most press coverage and the longest run in mainstream conversation, not necessarily the best fit for any one patient.
Why This Matters Before You Book Anything
The practical concern the report raises is a visibility gap. If an AI chatbot is quietly becoming a first stop for treatment research the way search engines and social feeds once were, then a patient's very first mental shortlist may already be narrowed to a handful of the biggest names before they ever look at a local provider's credentials, before-and-after photos or consultation notes.
That is not a reason to distrust well-known brands, several of which have long safety track records precisely because of their scale and years of monitoring. It is a reason to treat an AI answer the same way you would treat a friend's recommendation: a decent starting point, not a substitute for sitting down with a licensed injector or laser provider who can look at your skin, your history and your goals in person.
What a Real Consultation Still Covers That a Chatbot Can't
An AI summary cannot examine your skin type, review your medication list, watch how your muscles move when you talk to gauge dosing needs, or confirm a provider's actual license and injection volume. It also cannot tell you whether a specific product is the right call for your anatomy versus an alternative from a smaller or newer brand that never shows up in a generic chatbot answer.
This is informational reporting on an industry data trend, not medical advice, and it is not a claim that any brand or provider will produce a specific outcome. The most useful next step after reading a headline stat like this one is the same as it always was: bring your questions to an in-person consultation, where a licensed clinician can walk through options, realistic expectations and any risks specific to you.
6 Questions Worth Asking Before You Trust an AI Treatment Recommendation
A chatbot answer can be a useful starting point for research, but these questions belong to an actual consultation, not a search box.
- Is the provider actually licensed for this treatment: Ask directly about credentials and who performs the injection or procedure, not just who owns the practice.
- Does this product fit my specific goals: A brand's popularity in AI answers says nothing about whether it is the right formulation or device for your face, skin type or timeline.
- What are the realistic risks and downtime: A good consultation covers bruising, swelling, and rare complications candidly, not just the upside.
- How many of these has the provider actually done: Experience with a specific technique or device matters more than which name is trending.
- What alternatives exist outside the big names: Smaller or newer brands can be well-suited to certain concerns even if they rarely surface in a generic AI answer.
- Is this treatment even necessary right now: A trustworthy provider will sometimes recommend waiting, a lighter approach, or skincare first.
Frequently Asked Questions
Does this report mean the top brands are the safest choice?
Not necessarily. The index measures how often a brand is mentioned in AI-generated answers, which correlates with marketing reach and market share, not with a clinical ranking of safety or suitability for any individual patient.
Which AI systems were included in the study?
The report evaluated ChatGPT, Claude, Perplexity, Gemini and Google AI Overviews, testing 65 patient-style prompts across 92 candidate brands in the aesthetic medicine category.
Should I stop using AI to research treatments?
AI tools can be a reasonable starting point for general education, but this data suggests they lean heavily toward a small number of major brands, so it is worth treating the answer as one input among several, not the final word.
Why does brand concentration matter for someone in Las Vegas?
It means a first mental shortlist formed from a chatbot may already skip smaller or newer options a local licensed provider could recommend, which is one more reason an in-person consultation is worth the extra step before booking anything.